Clinical Trials Logo

Lymphoma, Mantle-cell clinical trials

View clinical trials related to Lymphoma, Mantle-cell.

Filter by:
  • Recruiting  
  • « Prev · Page 15

NCT ID: NCT01322776 Recruiting - Clinical trials for Mantle Cell Lymphoma Recurrent

Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma

Start date: March 2011
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-center, single arm, open-label, prospective IIS study, which will enroll 40 recurrent MCL patients.The aim is to evaluate the efficacy and safety of bortezomib, fludarabine and cyclophosphamide treatment and also analyze the relationship between NF-kB activity and efficacy of bortezomib treatment and whether NF-kB activity can predict MCL progression.

NCT ID: NCT01221103 Recruiting - Clinical trials for Lymphoma, Mantle-Cell

Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)

Start date: April 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The rationale for this study design is based on the fact that the maximum tolerated dose (MTD) of single-agent ofatumumab and bendamustine have been previously determined. The choice of the doses for the combination is based on the investigators unpublished clinical experience, as well as inferred from extensive experimental data on the use of other monoclonal antibodies in combination chemotherapy in lymphoma patients. The starting dose of the 2 main component drugs is the MTD of each drug as single agent.

NCT ID: NCT00946374 Recruiting - Clinical trials for Mantle-Cell Lymphoma

Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma

HD-MCL2003
Start date: July 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to improve the overall survival of Mantle-Cell-Lymphoma (MCL) by a new concept of treatment with primary curative intention consisting of six courses of immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (SCT) and HLA-identical allogenic SCT after a dose-reduced conditioning regimen of total body irradiation (TBI) with 2 Gy and Fludarabine in younger patients with primary Mantle-Cell-Lymphoma

NCT ID: NCT00209222 Recruiting - Clinical trials for Lymphoma, Mantle-Cell

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

Start date: July 2004
Phase: Phase 3
Study type: Interventional

The aim of this study is to determine whether alternating courses of cyclophosphamide, doxorubicin, vincristine, prednisone/dexamethasone, cytarabine, cisplatin (CHOP/DHAP) plus rituximab followed by total body irradiation [TBI]/high dose cytarabine [ARA-C]/melphalan-peripheral blood stem cell transplantation (TAM-PBSCT) can improve the time to treatment failure compared to CHOP plus rituximab followed by standard PBSCT (dexamethasone, carmustine, cytarabine, etoposide, and melphalan [Dexa-BEAM]/TBI/high dose cyclophosphamide) in patients with untreated mantle cell lymphoma.